We conducted a retrospective study to analyze the prognostic factors impacting the overall survival (OS) and progression‐free survival (PFS) of diffuse large B‐cell lymphoma (DLBCL) patients undergoing first‐line therapy and admitted to intensive care unit (ICU) compared to a control cohort who did not required ICU admission. Between January 1, 2008, and December 31, 2018, 828 patients were diagnosed with DLBCL at our institution, including 72 patients who were required ICU admission during disease course. Among them, forty‐five patients undergoing homogeneous first‐line therapy with /R‐CHOP‐like regimen and ICU‐admitted were selected for the present analysis. Control “non‐ICU” DLBCL patients were matched by age, IPI score and treatment received. The median age at ICU admission was 65 years, 97.8% of patients displayed advanced‐stage disease (III/IV), and 84.4% had a high IPI score (3‐5). The main reasons for ICU admission were acute respiratory failure (40.0%) and septic shock (33.3%). The ICU mortality rate was 33.3%. The 2‐year PFS was lower in ICU survivors patients than in non‐ICU patients: 31.7% (95% CI 18.5‐54.1) vs 60.8% (95% CI 51.2‐72.1, P = .00049). Admission to the ICU is an event that clearly impacts the outcomes of patients with DLBCL, until 2 years after the event. ICU prognosis seems mainly related to critical patient severity at admission rather than lymphoma‐related prognostic factors (IPIs), suggesting that ICU admission criteria should not be based only on the lymphoma prognosis.

Mixed-phenotype leukemia (MPAL) is a rare and high-risk subtype of leukemia accounting for less than 1% of all leukemias. No consensus exists regarding appropriate treatment. We report a patient with PICALM/AF10 T/myeloid MPAL who reached durable complete molecular remission after acute myeloid leukemia (AML)-like treatment. Mixed-phenotype acute leukemia is a heterogeneous group of leukemias that is extremely rare, accounting for less than 1% of all acute leukemias. 1 Several hematopoiesis patterns have been proposed to explain this mixed phenotype, but the hematopoiesis is more complex than linear models. We report the case of a young man who developed T/myeloid mixed-phenotype leukemia with extranodal damage and translocation (10;11)(p13;q14) PICALM/AF10. The translocation (10;11)(p13; q14) PICALM/AF10 is described in multilineage blood disease, but the physiopathology of PICALM/ AF10-mediated leukemia remains unresolved. PICALM (phosphatidylinositol-binding clathrin assembly protein, or CALM) is a ubiquitously expressed protein involved in clathrin-mediated endocytosis and iron homeostasis. 2 AF10 is a transcriptional factor and one of the fusion partners of MLL. The patient achieved complete and durable remission with an AML regimen (3 + 7), followed by HLA-matched unrelated allogeneic stem cell transplantation. Because of limited available data, no gold standard of care exists. An acute lymphoblastic leukemia (ALL)-like regimen followed by allogeneic

No abstract

No abstract